Metabotropic glutamate receptors in neurodegeneration/neuroprotection: Still a hot topic?

Moving from early studies, we here review the most recent evidence linking metabotropic glutamate (mGlu) receptors to processes of neurodegeneration/neuroprotection. The use of knockout mice and subtype-selective drugs has increased our knowledge of the precise role played by individual mGlu receptor subtypes in these processes. Activation of mGlu1 and mGlu5 receptors may either amplify or reduce neuronal damage depending on the context and the nature of the toxic insults. In contrast, mGlu1 and mGlu5 receptors antagonists are consistently protective in in vitro and in vivo models of neuronal death. A series of studies suggest that mGlu1 receptor antagonists or negative allosteric modulators (NAMs) are promising candidates for the treatment of ischemic brain damage, whereas mGlu5 receptor NAMs, which have been clinically developed for the treatment of Parkinson's disease (PD) and l-DOPA-induced dyskinesias, protect nigro-striatal dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity in mice and monkeys. Activation of glial mGlu3 receptors promotes the formation of various neurotrophic factors, such as transforming growth factor-β (TGF-β), glial-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and brain-derived neurotrophic factor (BDNF). Hence, selective mGlu3 receptor agonists or positive allosteric modulators (PAMs) (not yet available) are potentially helpful in the treatment of chronic neurodegenerative disorders such as PD, Alzheimer's disease (AD), and amyotrophic lateral sclerosis. Selective mGlu2 receptor PAMs should be used with caution in AD patients because these drugs are shown to amplify β-amyloid neurotoxicity. Finally, mGlu4 receptor agonists/PAMs share with mGlu5 receptor NAMs the ability to improve motor symptoms associated with PD and attenuate nigro-striatal degeneration at the same time. No data are yet available on the role of mGlu7 and mGlu8 receptors in neurodegeneration/neuroprotection.

[1]  A. Volterra,et al.  Focal degeneration of astrocytes in amyotrophic lateral sclerosis , 2008, Cell Death and Differentiation.

[2]  P. Ornstein,et al.  Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo. , 2000, The Journal of pharmacology and experimental therapeutics.

[3]  E. Nisenbaum,et al.  Targeting Group II Metabotropic Glutamate (mGlu) Receptors for the Treatment of Psychosis Associated with Alzheimer's Disease: Selective Activation of mGlu2 Receptors Amplifies β-Amyloid Toxicity in Cultured Neurons, Whereas Dual Activation of mGlu2 and mGlu3 Receptors Is Neuroprotective , 2011, Molecular Pharmacology.

[4]  F. Nicoletti,et al.  Activation of group III metabotropic glutamate receptors is neuroprotective in cortical cultures. , 1996, European journal of pharmacology.

[5]  F. Gasparini,et al.  Selective Activation of mGlu4 Metabotropic Glutamate Receptors Is Protective against Excitotoxic Neuronal Death , 2000, The Journal of Neuroscience.

[6]  M. O'Neill,et al.  LY379268, a potent and selective Group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal, cerebral ischaemia , 1999, Neuroscience Letters.

[7]  W. Danysz,et al.  Neuroprotective potential of group I metabotropic glutamate receptor antagonists in two ischemic models , 2006, Neurochemistry International.

[8]  R. Balázs,et al.  Metabotropic Glutamate Receptor mGluR5 in Astrocytes: Pharmacological Properties and Agonist Regulation , 1997, Journal of neurochemistry.

[9]  M. Heilig,et al.  Alcohol-Induced Neurodegeneration, Suppression of Transforming Growth Factor-β, and Cognitive Impairment in Rats: Prevention by Group II Metabotropic Glutamate Receptor Activation , 2010, Biological Psychiatry.

[10]  F. Nicoletti,et al.  Estrogen Receptors and Type 1 Metabotropic Glutamate Receptors Are Interdependent in Protecting Cortical Neurons against β-Amyloid Toxicity , 2012, Molecular Pharmacology.

[11]  B. Hemmings,et al.  Ten years of protein kinase B signalling: a hard Akt to follow. , 2001, Trends in biochemical sciences.

[12]  D. Jane,et al.  Pharmacological agents acting at subtypes of metabotropic glutamate receptors , 1999, Neuropharmacology.

[13]  F. Moroni,et al.  Involvement of endocannabinoid signaling in the neuroprotective effects of subtype 1 metabotropic glutamate receptor antagonists in models of cerebral ischemia. , 2009, International review of neurobiology.

[14]  N. Belluardo,et al.  Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain , 2010, Neuroscience.

[15]  P. Bosco,et al.  The CC genotype of transforming growth factor-β1 increases the risk of late-onset Alzheimer's disease and is associated with AD-related depression , 2012, European Neuropsychopharmacology.

[16]  F. Nicoletti,et al.  The Use of Knock-Out Mice Unravels Distinct Roles for mGlu2 and mGlu3 Metabotropic Glutamate Receptors in Mechanisms of Neurodegeneration/Neuroprotection , 2007, The Journal of Neuroscience.

[17]  P Jeffrey Conn,et al.  Group III Metabotropic Glutamate Receptor-Mediated Modulation of the Striatopallidal Synapse , 2003, The Journal of Neuroscience.

[18]  A. Dilella,et al.  Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  G Bernardi,et al.  Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons , 2001, Neuroscience.

[20]  F. Nicoletti,et al.  Pharmacological Activation of mGlu4 Metabotropic Glutamate Receptors Reduces Nigrostriatal Degeneration in Mice Treated with 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine , 2006, The Journal of Neuroscience.

[21]  G. Collingridge,et al.  (RS)-2-Chloro-5-Hydroxyphenylglycine (CHPG) Activates mGlu5, but not mGlu1, Receptors Expressed in CHO Cells and Potentiates NMDA Responses in the Hippocampus , 1997, Neuropharmacology.

[22]  E. Aronica,et al.  Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins , 2003, The European journal of neuroscience.

[23]  B. Kinon,et al.  A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia , 2011, Journal of clinical psychopharmacology.

[24]  S. Traynelis,et al.  Metabotropic Glutamate Receptors 1 and 5 Differentially Regulate CA1 Pyramidal Cell Function , 2001, The Journal of Neuroscience.

[25]  E. Nagata,et al.  PI3 kinase enhancer–Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis , 2003, Nature Neuroscience.

[26]  F. Nicoletti,et al.  A prolonged pharmacological blockade of type-5 metabotropic glutamate receptors protects cultured spinal cord motor neurons against excitotoxic death , 2011, Neurobiology of Disease.

[27]  F. Nicoletti,et al.  Activation of A1 adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S‐100β protein from cultured astrocytes , 1999, Glia.

[28]  P. Calabresi,et al.  Selective Blockade of Type-1 Metabotropic Glutamate Receptors Induces Neuroprotection by Enhancing Gabaergic Transmission , 2001, Molecular and Cellular Neuroscience.

[29]  F. Nicoletti,et al.  Retracted: Neuroprotection mediated by glial group‐II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol‐3‐kinase pathways , 2001, Journal of neurochemistry.

[30]  J. Olney,et al.  Glutamate and the pathophysiology of hypoxic–ischemic brain damage , 1986, Annals of neurology.

[31]  Wei Xu,et al.  Neuroprotection against neonatal hypoxia/ischemia-induced cerebral cell death by prevention of calpain-mediated mGluR1α truncation , 2009, Experimental Neurology.

[32]  S. Urwyler,et al.  Novel N-methyl-d-aspartate receptor antagonists: a review of compounds patented since 2006 , 2010, Expert opinion on therapeutic patents.

[33]  J. Rothstein Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis. , 1995, Clinical neuroscience.

[34]  Andreas Schober,et al.  GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-β for its neuroprotective action , 2007, Neurobiology of Disease.

[35]  E. Aronica,et al.  Immunohistochemical localization of group I and II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: upregulation in reactive astrocytes , 2001, Neuroscience.

[36]  L. Mucke,et al.  Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. , 2006, The Journal of clinical investigation.

[37]  J. Olney THE TOXIC EFFECTS OF GLUTAMATE AND RELATED COMPOUNDS IN THE RETINA AND THE BRAIN , 1982, Retina.

[38]  D. Laurie,et al.  (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. , 1999, The Journal of pharmacology and experimental therapeutics.

[39]  X. C. Lu,et al.  Neuroprotection mediated by glutamate carboxypeptidase II (NAALADase) inhibition requires TGF-beta. , 2001, European journal of pharmacology.

[40]  D. Linden,et al.  Homer Binds a Novel Proline-Rich Motif and Links Group 1 Metabotropic Glutamate Receptors with IP3 Receptors , 1998, Neuron.

[41]  N. Belluardo,et al.  Activation of mGlu3 Receptors Stimulates the Production of GDNF in Striatal Neurons , 2009, PloS one.

[42]  P. Mermelstein Membrane‐Localised Oestrogen Receptor α and β Influence Neuronal Activity Through Activation of Metabotropic Glutamate Receptors , 2009, Journal of neuroendocrinology.

[43]  A. Brownell,et al.  Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease , 2010, Neuroscience Letters.

[44]  B. Meldrum Protection against ischaemic neuronal damage by drugs acting on excitatory neurotransmission. , 1990, Cerebrovascular and brain metabolism reviews.

[45]  D. Choi,et al.  The inhibitory mGluR agonist, s-4-carboxy-3-hydroxy-phenylglycine selectively attenuates NMDA neurotoxicity and oxygen-glucose deprivation-induced neuronal death , 1995, Neuropharmacology.

[46]  J. Wroblewski,et al.  Dual neurotoxic and neuroprotective role of metabotropic glutamate receptor 1 in conditions of trophic deprivation – Possible role as a dependence receptor , 2008, Neuropharmacology.

[47]  J. Mcculloch,et al.  Effects of the selective metabotropic glutamate agonist LY354740 in a rat model of permanent ischaemia , 1998, Neuroscience Letters.

[48]  P. Worley,et al.  Coupling of mGluR/Homer and PSD-95 Complexes by the Shank Family of Postsynaptic Density Proteins , 1999, Neuron.

[49]  K. Reymann,et al.  The mGlu receptor ligand (S)‐4C3HPG protects neurons after global ischaemia in gerbils , 1998, Neuroreport.

[50]  M. Miras-Portugal,et al.  Functional Switch from Facilitation to Inhibition in the Control of Glutamate Release by Metabotropic Glutamate Receptors* , 1998, The Journal of Biological Chemistry.

[51]  D. Choi,et al.  Reducing calcium overload in the ischemic brain. , 1999, The New England journal of medicine.

[52]  F. Nicoletti,et al.  The cell cycle molecules behind neurodegeneration in Alzheimer's disease: perspectives for drug development. , 2008, Current medicinal chemistry.

[53]  J. Lile,et al.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.

[54]  E. Meli,et al.  Activation of mGlu1 but not mGlu5 metabotropic glutamate receptors contributes to postischemic neuronal injury in vitro and in vivo , 2002, Pharmacology Biochemistry and Behavior.

[55]  Kari A. Johnson,et al.  Discovery, Characterization, and Antiparkinsonian Effect of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4 , 2008, Molecular Pharmacology.

[56]  H. Shinozaki,et al.  Activation of Class II or III Metabotropic Glutamate Receptors Protects Cultured Cortical Neurons Against Excitotoxic Degeneration , 1995, The European journal of neuroscience.

[57]  F. Nicoletti,et al.  Chapter 14 Metabotropic glutamate receptors and neurodegeneration , 1998 .

[58]  G. Albers,et al.  N‐methyl‐D‐aspartate antagonists: Ready for clinical trial in brain ischemia? , 1989, Annals of neurology.

[59]  J. Wroblewski,et al.  The Protective Signaling of Metabotropic Glutamate Receptor 1 Is Mediated by Sustained, β-Arrestin-1-dependent ERK Phosphorylation* , 2010, The Journal of Biological Chemistry.

[60]  F. Nicoletti,et al.  Protective Role for Type 4 Metabotropic Glutamate Receptors against Ischemic Brain Damage , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[61]  D. Choi,et al.  Glutamate neurotoxicity and diseases of the nervous system , 1988, Neuron.

[62]  F. Nicoletti,et al.  Metabotropic glutamate receptors and neurodegeneration. , 1998 .

[63]  P. Bramanti,et al.  Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease , 2006, Neurobiology of Disease.

[64]  R. Gereau,et al.  Metabotropic glutamate receptor 5 antagonism with fenobam: examination of analgesic tolerance and side effect profile in mice. , 2011, Anesthesiology.

[65]  F. Nicoletti,et al.  Metabotropic Glutamate Receptor Subtypes as Targets for Neuroprotective Drugs , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[66]  P. Bosco,et al.  Dysfunction of TGF-β1 signaling in Alzheimer’s disease: perspectives for neuroprotection , 2011, Cell and Tissue Research.

[67]  C. Cotman,et al.  Exposure of Astrocytes to Thrombin Reduces Levels of the Metabotropic Glutamate Receptor mGluR5 , 1996, Journal of neurochemistry.

[68]  S. Fracchia,et al.  Metabotropic glutamate receptors negatively coupled to adenylate cyclase inhibit N-methyl-D-aspartate receptor activity and prevent neurotoxicity in mesencephalic neurons in vitro. , 1995, Molecular pharmacology.

[69]  J. Olney,et al.  Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies. , 1997, Archives of neurology.

[70]  B. Siesjö,et al.  The Biochemical Basis of Cerebral Ischemic Damage , 1995, Journal of neurosurgical anesthesiology.

[71]  M. Scheideler,et al.  The novel and systemically active metabotropic glutamate 1 (mGlu1) receptor antagonist 3-MATIDA reduces post-ischemic neuronal death , 2002, Neuropharmacology.

[72]  J. Vry,et al.  Neuroprotective and behavioral effects of the selective metabotropic glutamate mGlu(1) receptor antagonist BAY 36-7620. , 2001, European journal of pharmacology.

[73]  F. Nicoletti,et al.  Selective activation of group-II metabotropic glutamate receptors is protective against excitotoxic neuronal death. , 1998, European journal of pharmacology.

[74]  H. Shinozaki,et al.  Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death. , 1994, European journal of pharmacology.

[75]  F. Moroni,et al.  Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges , 2001, British journal of pharmacology.

[76]  D. Choi,et al.  Glutamate receptors and the induction of excitotoxic neuronal death. , 1994, Progress in brain research.

[77]  Anna L. Blobaum,et al.  Discovery, synthesis, and structure-activity relationship development of a series of N-(4-acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)) with CNS exposure in rats. , 2011, Journal of medicinal chemistry.

[78]  K. Tanonaka,et al.  mGluR1 antagonist decreases tyrosine phosphorylation of NMDA receptor and attenuates infarct size after transient focal cerebral ischemia , 2008, Journal of neurochemistry.

[79]  P. Conn,et al.  Metabotropic glutamate receptors: physiology, pharmacology, and disease. , 2010, Annual review of pharmacology and toxicology.

[80]  F. Nicoletti,et al.  The Neuroprotective Activity of Group-II Metabotropic Glutamate Receptors Requires New Protein Synthesis and Involves a Glial–Neuronal Signaling , 1997, The Journal of Neuroscience.

[81]  K. Bales,et al.  Neuroprotection by metabotropic glutamate receptor agonists: LY354740, LY379268 and LY389795 , 1999 .

[82]  J. Harris,et al.  Neuroprotective Actions of Novel and Potent Ligands of Group I and Group II Metabotropic Glutamate Receptors , 1999, Annals of the New York Academy of Sciences.

[83]  P. Jeffrey Conn,et al.  Metabotropic glutamate receptors in the basal ganglia motor circuit , 2005, Nature Reviews Neuroscience.

[84]  F. Moroni,et al.  CB1 receptors and post-ischemic brain damage: Studies on the toxic and neuroprotective effects of cannabinoids in rat organotypic hippocampal slices , 2011, Neuropharmacology.

[85]  Daniela Berg,et al.  Treatment of Levodopa-Induced Dyskinesias : Results of 2 Randomized Controlled Trials , 2011 .

[86]  H. Kinouchi,et al.  Neuroprotective effects of group II metabotropic glutamate receptor agonist DCG-IV on hippocampal neurons in transient forebrain ischemia , 2009, Neuroscience Letters.

[87]  F. Nicoletti,et al.  Metabotropic glutamate receptors: From the workbench to the bedside , 2011, Neuropharmacology.

[88]  F. Nicoletti,et al.  Group-I metabotropic glutamate receptors: hypotheses to explain their dual role in neurotoxicity and neuroprotection , 1999, Neuropharmacology.

[89]  M. Baudry,et al.  Calpain-Mediated mGluR1α Truncation: A Key Step in Excitotoxicity , 2007, Neuron.

[90]  F. Nicoletti,et al.  Neuroprotection by Glial Metabotropic Glutamate Receptors Is Mediated by Transforming Growth Factor-β , 1998, The Journal of Neuroscience.

[91]  Seiji Tamura,et al.  Neuroprotective effects of the selective type 1 metabotropic glutamate receptor antagonist YM-202074 in rat stroke models , 2008, Brain Research.

[92]  D. Pellegrini-Giampietro The distinct role of mGlu1 receptors in post-ischemic neuronal death. , 2003, Trends in pharmacological sciences.

[93]  U. Dirnagl,et al.  Distinct influence of the group III metabotropic glutamate receptor agonist (R,S)-4-phosphonophenylglycine [(R,S)-PPG] on different forms of neuronal damage , 2000, Neuropharmacology.

[94]  C. Cotman,et al.  Growth factor upregulation of a phosphoinositide-coupled metabotropic glutamate receptor in cortical astrocytes , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[95]  T. Wichmann,et al.  Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. , 2011, Brain : a journal of neurology.

[96]  S. Lipton Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond , 2006, Nature Reviews Drug Discovery.

[97]  I. Vranesic,et al.  (−)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection , 2003, Neuropharmacology.

[98]  Giuseppe Battaglia,et al.  Endogenous Activation of mGlu5 Metabotropic Glutamate Receptors Contributes to the Development of Nigro-Striatal Damage Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in Mice , 2004, The Journal of Neuroscience.

[99]  F. Moroni,et al.  Neuroprotection by group I mGlu receptors in a rat hippocampal slice model of cerebral ischemia is associated with the PI3K–Akt signaling pathway: A novel postconditioning strategy? , 2008, Neuropharmacology.

[100]  C. Cotman,et al.  Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[101]  F. Moroni,et al.  Differential role of mGlu1 and mGlu5 receptors in rat hippocampal slice models of ischemic tolerance , 2007, The European journal of neuroscience.

[102]  P. Mermelstein,et al.  Membrane Estrogen Receptors Acting Through Metabotropic Glutamate Receptors: An Emerging Mechanism of Estrogen Action in Brain , 2008, Molecular Neurobiology.

[103]  R. Pellicciari,et al.  (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-phenylcyclopropyl)glycine, a potent and selective antagonist of type 2 metabotropic glutamate receptors. , 1996, Molecular pharmacology.

[104]  F. Nicoletti,et al.  Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide. , 1995, Molecular pharmacology.

[105]  H. Bading,et al.  Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders , 2010, Nature Reviews Neuroscience.

[106]  D. Brooks,et al.  Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.

[107]  Francesco Ferraguti,et al.  Metabotropic glutamate receptors , 2006, Cell and Tissue Research.

[108]  S. Mosolov,et al.  Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.

[109]  K. Tanonaka,et al.  mGluR1 antagonist decreased NADPH oxidase activity and superoxide production after transient focal cerebral ischemia , 2010, Journal of neurochemistry.

[110]  S. Pfaff,et al.  Fine-Tuning Motor Neuron Properties Signaling from the Periphery , 2002, Neuron.

[111]  M. O'Neill,et al.  Neuroprotective effects of a systemically active Group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia , 1998, Neuroreport.

[112]  E. Meli,et al.  Metabotropic glutamate 1 (mGlu1) receptor antagonists enhance GABAergic neurotransmission: a mechanism for the attenuation of post-ischemic injury and epileptiform activity? , 2002, Neuropharmacology.

[113]  S. Duty Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease , 2010, British journal of pharmacology.

[114]  Mark H. Ellisman,et al.  Alterations in mGluR5 Expression and Signaling in Lewy Body Disease and in Transgenic Models of Alpha-Synucleinopathy – Implications for Excitotoxicity , 2010, PloS one.

[115]  G. Gerhardt,et al.  Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. , 2005, Journal of neurosurgery.

[116]  F. Jensen,et al.  Developmental regulation of group I metabotropic glutamate receptors in the premature brain and their protective role in a rodent model of periventricular leukomalacia. , 2010, Neuron glia biology.

[117]  Deanna L. Taylor,et al.  Activation of Microglial Group III Metabotropic Glutamate Receptors Protects Neurons against Microglial Neurotoxicity , 2002, The Journal of Neuroscience.

[118]  C. Barnes,et al.  Homer: a protein that selectively binds metabotropic glutamate receptors , 1997, Nature.

[119]  P. Lipton,et al.  Ischemic cell death in brain neurons. , 1999, Physiological reviews.